No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI.
作者信息
Valgimigli Marco, Gragnano Felice
机构信息
Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
Ann Transl Med. 2020 Apr;8(7):516. doi: 10.21037/atm.2020.01.26.
Abstract
摘要
相似文献
1
No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI.没有免费的午餐——急性冠状动脉综合征或经皮冠状动脉介入治疗后房颤患者双联与三联抗栓治疗的代价。
Ann Transl Med. 2020 Apr;8(7):516. doi: 10.21037/atm.2020.01.26.
2
From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome.从WOEST研究到AUGUSTUS研究：房颤患者急性冠状动脉综合征行经皮冠状动脉介入治疗时三联与双联抗栓方案的安全性和有效性综述
Ann Transl Med. 2019 Sep;7(17):405. doi: 10.21037/atm.2019.08.21.
3
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal.心房颤动合并急性冠状动脉综合征/经皮冠状动脉介入治疗中双联与三联抗栓治疗的随机试验和荟萃分析：一项批判性评估。
Int J Cardiol Heart Vasc. 2020 May 14;28:100524. doi: 10.1016/j.ijcha.2020.100524. eCollection 2020 Jun.
4
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.抗栓治疗在房颤和急性冠脉综合征患者中治疗药物或经皮冠状动脉介入或接受择期经皮冠状动脉介入治疗:从 AUGUSTUS 试验的见解。
Circulation. 2019 Dec 3;140(23):1921-1932. doi: 10.1161/CIRCULATIONAHA.119.043308. Epub 2019 Sep 26.
5
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.经皮冠状动脉介入治疗（PCI）后伴有心房颤动患者的口服抗凝药物转换：RE-DUAL PCI 试验亚组分析。
JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039.
6
Antithrombotic strategies and outcomes in acute coronary syndrome with atrial fibrillation.急性冠状动脉综合征合并心房颤动的抗栓策略及结局
Am J Cardiol. 2015 Apr 15;115(8):1042-8. doi: 10.1016/j.amjcard.2015.01.534. Epub 2015 Jan 31.
7
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.达比加群双重治疗与华法林三联治疗用于伴有糖尿病的房颤患者经皮冠状动脉介入术后
JACC Cardiovasc Interv. 2019 Dec 9;12(23):2346-2355. doi: 10.1016/j.jcin.2019.07.059.
8
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.在 PCI 后合并房颤的患者中，达比加群双联抗栓治疗的肾脏功能和结局。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050.
9
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.房颤患者 PCI 术后的达比加群双重抗血栓治疗。
N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.
10
Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?经皮冠状动脉介入治疗（PCI）的房颤患者的抗栓治疗：双联治疗是赢家吗？
Thromb Res. 2019 Apr;176:133-139. doi: 10.1016/j.thromres.2019.02.022. Epub 2019 Feb 22.
本文引用的文献
1
Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.AUGUSTUS试验中接受冠状动脉支架置入术的房颤患者的支架内血栓形成
Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11.
2
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.经皮冠状动脉介入治疗后心房颤动患者双联与三联抗栓治疗的安全性和疗效结局：基于非维生素 K 拮抗剂口服抗凝剂的随机临床试验的系统评价和荟萃分析。
Eur Heart J. 2019 Dec 7;40(46):3757-3767. doi: 10.1093/eurheartj/ehz732.
3
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.依度沙班与维生素 K 拮抗剂在房颤患者成功经皮冠状动脉介入治疗后抗栓治疗方案的比较（ENTRUST-AF PCI）：一项随机、开放标签、3b 期临床试验。
Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.
4
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.经皮冠状动脉介入治疗（PCI）的心房颤动患者抗栓治疗管理：美国心脏病学会的现状评估。
J Am Coll Cardiol. 2019 Jul 9;74(1):83-99. doi: 10.1016/j.jacc.2019.05.016.
5
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.心房颤动急性冠状动脉综合征或经皮冠状动脉介入治疗后的抗血栓治疗。
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
6
A call for action in bleeding prevention.预防出血的行动呼吁。
Aging (Albany NY). 2019 Jan 11;11(2):287-288. doi: 10.18632/aging.101745.
7
Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?三联抗栓治疗，或者更确切地说，其疗程和组成，是接受冠状动脉介入治疗的房颤患者出血事件过多的真正原因吗？
Eur Heart J. 2019 Jan 7;40(2):216-217. doi: 10.1093/eurheartj/ehy675.
8
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry.当代真实世界实践中急性冠状动脉综合征患者的流行病学与管理：从EYESHOT研究到START-抗血小板治疗注册研究的演变趋势
Angiology. 2018 Oct;69(9):795-802. doi: 10.1177/0003319718760917. Epub 2018 Mar 15.
9
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的冠状动脉疾病双联抗血小板治疗重点更新：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
10
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.房颤患者 PCI 术后的达比加群双重抗血栓治疗。
N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.
Zotero 插件